Items Tagged ‘PDL1’

February 26th, 2015

FDA Grants Breakthrough Therapy Designation for MPDL3280A, an anti-PDL1 Investigational Cancer Immunotherapy for Non-Small Cell Lung Cancer


The investigational cancer immunotherapy MPDL3280A (anti-PDL1) has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). The designation was granted for the treatment of people with PD-L1 (Programmed Death-Ligand 1) positive non-small cell lung cancer (NSCLC) whose disease has progressed during or after platinum-based chemotherapy. Lung cancer remains the leading cause of […]

View full entry

Tags: anti-PDL1, Breakthrough Therapy Designation, Lung Cancer, Lung Cancer - Non-Small Cell, MPDL3280A, News, non-small cell lung cancer, nsclc, PDL1, Recurrent Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell